Press Releases


DORAL, FL–(Marketwired – Dec 8, 2014) – In Ovations Holdings, Inc. (OTC PINK: INOH) has concluded negotiations and due diligence and has entered into a sales and marketing agreement with Regulon, Inc. (“Regulon”) for the marketing and sale of Regulon’s anti-cancer therapies. The parties will leverage INOH’s access to markets including the Caribbean in order to broaden the awareness and sale of their cancer detection and treatment products. The global cancer market was $75-80 billion in 2013. Sales of platinum-based chemotherapy drugs (cisplatin, carboplatin, oxaliplatin) were $2.6 bn (in seven major pharmaceutical markets) in 2008. Regulon designs and produces the following anti-cancer drugs: LipoPlatin™, LipoXal™, LipoVil-12™. Regulon has developed a unique liposome encapsulation technology applicable to drugs such as cisplatin, a cytotoxic agent, small molecules, peptides, proteins and viruses aiming at improving human lives and reducing the side effects of chemotherapy known to exacerbate the quality of life of cancer patients. Regulon is currently engaged in active sales. Recent studies showed that platinum-based chemotherapy drugs share is growing. The platinum drug market is anticipated to increase tremendously after cisplatin, a cytotoxin agent, is replaced by Regulon’s LipoPlatin™. Regulon is a private biopharmaceutical company committed to the discovery and development of nano-pharmaceutics in oncology which has raised over $30,000,000 in the private marketplace in countries including Greece, Cyprus, Austria, Turkey, Korea, Brazil, Taiwan, Israel, and Lebanon. Teni Boulikas, PhD., President and CEO of Regulon, stated: “After establishing a solid base in Europe and breaking into the Asian market, we are pleased to partner with INOH. We view this relationship as symbiotic, offering INOH’s clients cancer solutions from detection to treatment. We look forward to the introduction of Regulon’s products to the Caribbean markets.” Mark Goldberg, Co-CEO of INOH, added: “After the recent phase of technology acquisition by INOH culminating in the launching of sputum cytology products, developed by Mel Ehrlich, Ph.D., reaching end-users is our primary goal.” Co-CEO Rosendo Alvarez, III added, “We are thrilled to enter this association with Regulon and to augment our companies’ offerings to purchasers of cancer-related technologies. The mutual introduction to additional markets is the beginning of a new phase with significant growth potential for both companies.” INOH’s recently formed Medical Advisory Committee http://inovationsholdings.com/medical-advisory-board/  is a an integral part of its oversight of these projects. A comprehensive evaluation of INOH’s sputum cytology technology appears on its website: http://inovationsholdings.com/cytometry/ Regulon’s comprehensive corporate and scientific profile can be viewed at http://www.regulon.org/ Background INOH continues to pursue several potential business opportunities outside of the cancer-related field. Its subsidiary, Electro Verde, Inc., markets, in conjunction with Coordinated Systems International, the patented GradiLuxtm Total Lighting System Solution which can reduce electricity consumption and carbon emissions in municipal...

Read More

DORAL, FL–(Marketwired – Jul 2, 2014) – In Ovations Holdings, Inc. (OTC Pink: INOH) (PINKSHEETS: INOH) is pleased to announce the implementation of the technology using sputum cytology for the early detection of lung cancer, a recognized laboratory procedure similar to the “Pap” test. Mel Ehrlich, Ph.D. stated, “I am pleased with the diligent efforts that In Ovations Holdings, Inc. is implementing with the sputum cytology technology for the early detection of lung cancer.” INOH is on a fast track and will keep its investors and the public updated. Lung cancer detection is presently slow, labor-intensive, expensive and not always effective until the cancer has developed which is often too late. Dr. Ehrlich’s scanning “microspectrophotometer” can detect cancer before it develops through analysis of the shape of pre-cancerous lung cells. It uses ultraviolet absorption of unstained cells which is cost effective, can be done in real time, and can have a higher confidence level of accuracy. A UV light beam produces a “raster” — an area which is scanned from side to side in lines from top to bottom. Dr. Ehrlich and his team are presently increasing the accuracy and speed of the cytology scanner for clinical laboratory use. A comprehensive evaluation of Dr. Ehrlich’s sputum cytology technology is available on the Company’s website: http://inovationsholdings.com/cytometry/. Background: In Ovations Holdings, Inc. is pursuing several potential business opportunities. Its subsidiary, Electro Verde, Inc., markets, in conjunction with Coordinated Systems International, the patented GradiLuxtm Total Lighting System Solution which can reduce electricity consumption and carbon emissions in municipal lighting systems worldwide. The Company is also engaged in a Caribbean-based marine-related eco-tourism business and ocean search and recovery operations using state-of-the-art technology. Finally, it is a minority owner of Atmospheric Water Solutions, a company involved in water purification. Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated. Contact: Public/Investor Relations: Premier Business Advisors Inc. William A. Young Sr. Phone: 623-238-5245 Email: wayoung55@aol.com Company Email: inovationsholdingsinc@gmail.com Website: www.inovationsholdings.com Facebook: InOvationHoldings...

Read More

DORAL, FL–(Marketwired – Jun 18, 2014) – In Ovations Holdings, Inc. (OTC Pink: INOH) (PINKSHEETS: INOH) announces that it intends to commence its early detection testing for lung cancer using the sputum cytology technology licensed from its Vice-President of Technology, Mel Ehrlich, Ph.D. Lung cancer early detection testing will be under the supervision of Dr. Osiris Madera, the Company’s new Caribbean Health Markets advisor, formerly the Dominican Republic’s Deputy Minister of Health. Dr. Madera has extensive experience in ultrasound, management of health systems and institutional planning and management. He received his M.D. degree from Universidad Nacional Pedro Henriquez Ureña (UNPHU) in Santo Domingo. Dr. Madera earned an MSc in endocrinology and nutrition from the Ibero-American School of Endocrinology and Nutrition, Madrid, Spain as well as an MSc in Nuclear Medicine from the Universidad Complutense de Madrid, Spain and attended the Ultrasonic School of New York. He owns an integral health center, Centro Integral de Salud, in the Dominican Republic which is recognized across the Caribbean and Central America. Dr. Madera is an active member of the Royal College of Physicians of Madrid, Spain; Latin American Association of Planners, San Jose, Costa Rica; and the Medical Association of the Dominican Republic. Background: In Ovations Holdings, Inc. is pursuing several potential business opportunities. Its subsidiary, Electro Verde, Inc., markets, in conjunction with Coordinated Systems International, the patented GradiLux™ Total Lighting System Solution which can reduce electricity consumption and carbon emissions in municipal lighting systems worldwide. The Company is also engaged in a Caribbean-based marine-related eco-tourism business and ocean search and recovery operations using state-of-the-art technology. Finally, it is a minority owner of Atmospheric Water Solutions, a company involved in water purification. Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated. Contact: Public/Investor Relations: Premier Business Advisors Inc. William A. Young Sr. Phone: 623-238-5245 Email: wayoung55@aol.com Company Email: inovationsholdingsinc@gmail.com Website: www.inovationsholdings.com Facebook:...

Read More

DORAL, FL–(Marketwired – Jun 10, 2014) – In Ovations Holdings, Inc. (OTC Pink: INOH) (PINKSHEETS: INOH) has concluded negotiations for licensing sophisticated sputum cytology technology for early and pre stage detection of lung cancer from Mel Ehrlich, Ph.D., who is also an officer and director of INOH. Dr. Ehrlich has invented, patented, perfected and marketed multiple biomedical and energy efficiency technologies. Pursuant to the license, INOH obtained exclusive rights to market the sputum cytology and related technologies world-wide from Dr. Ehrlich. Lung cancer detection is presently slow, labor-intensive, expensive and ineffective until the cancer has developed which is often too late. Dr. Ehrlich’s scanning “microspectrophotometer” can detect cancer before it develops through analysis of the shape of pre-cancerous lung cells. It uses ultraviolet absorption of unstained cells which is cost effective, can be done in real time, and can have a higher confidence level of accuracy. This UV light beam produces a “raster” — an area which is scanned from side to side in lines from top to bottom from two oscillating mirrors. Dr. Ehrlich and his team are presently increasing the accuracy and speed of the cytology scanner for commercial use. A comprehensive evaluation of Dr. Ehrlich’s sputum cytology technology is available on the Company’s website: http://inovationsholdings.com/cytometry/ Background In Ovations Holdings, Inc. is pursuing several potential business opportunities. Its subsidiary, Electro Verde, Inc., markets, in conjunction with Coordinated Systems International, the patented GradiLuxtm Total Lighting System Solution which can reduce electricity consumption and carbon emissions in municipal lighting systems worldwide. The Company is also engaged in a Caribbean-based marine-related eco-tourism business and ocean search and recovery operations using state-of-the-art technology. Finally, it is a minority owner of Atmospheric Water Solutions, a company involved in water purification. Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated. Contact: Public/Investor Relations: Premier Business Advisors Inc. William A. Young Sr. Phone: 623-238-5245 Email: wayoung55@aol.com Company Email: inovationsholdingsinc@gmail.com Website: www.inovationsholdings.com Facebook:...

Read More

DORAL, FL–(Marketwired – May 14, 2014) – In Ovations Holdings, Inc. (OTC Pink: INOH) (PINKSHEETS: INOH) (the “Company”) announces its has bought back a total of 600 million shares of the Company’s Common Stock Shares. Those Shares have been retired back to the Companies Treasury. The Chief Executive Officer Mark Goldberg, said, “The Company is focused on several projects which are expected to be profitable. By reducing the number of outstanding Shares, in the event our projections are actualized the Company would generate meaningful earnings per share.” About: In Ovations Holdings, Inc. In Ovations Holdings, Inc. is pursuing several potential opportunities. Its subsidiary, Electro Verde, Inc. is marketing, in conjunction with CSI the patented GradiLux™ Total Lighting System Solution which reduces electricity consumption and carbon emissions in municipal lighting systems worldwide. The Company is also involved in a Caribbean-based marine-related eco-tourism business and ocean search and recovery operations using state-of-the-art technology. Finally, it is a minority owner of Atmospheric Water Solutions, a company involved in water purification. Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995 this press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated. Contact: Public / Investor Relations: William A. Young Sr. Ph: 623-238-5245 E-mail: wayoung55@aol.com INOH Website: http://inovationsholdings.com FACEBOOK:...

Read More

Apr 29, 2014 OTC Disclosure & News Service In Ovations Holdings, Inc. Has Appointed Mel Ehrlich, Ph.D. as a Director and Vice-President of Technology Effective April 28, 2014 DORAL, FL–(Marketwired – Apr 29, 2014) – In Ovations Holdings, Inc. (OTC Pink: INOH) (PINKSHEETS: INOH) has appointed Mel Ehrlich, Ph.D. as a Director and Vice-President of Technology effective April 28, 2014. Dr. Ehrlich is CEO of Nano Biomed, Inc., a company which has licensed patented nanoparticle technologies in which the nanoparticles deliver nitric oxide (NO). The Nano NO has been tested on animals for applications such as accelerated wound healing and sepsis. He is also CEO of Cytest Labs, Inc. Cytest Labs develops optical scanners using Ultra-Violet (UV) light and a pattern recognition computer to measure and analyze human body cell parameters. Cellular material is obtained from lung cells from deep early morning coughs. The system is designed for the early detection of lung cancer. From 2003 to the present, he has served as Chairman and Chief Executive Officer of Efficient Energy Conversion Systems, Inc. (EECS). EECS has designed and patented significant improvements in oil burners and internal combustion (IC) engines. A US patent was awarded to Dr. Ehrlich in Aug. 2010 for his “Plasma Plug” (Plasma is a fully ionized gas). Foreign patents have been granted and some are pending. This Arc Plug™ could replace the conventional spark plug in any IC engine as original equipment or as a replacement for spark plugs in existing engines. The Arc Plug is the same size as a traditional spark plug and uses additional electronics. Calculations indicate an improved gas mileage of 40%, increased power and the elimination of the catalytic converter. From 2002 to 2003, Dr. Ehrlich served as President and Chief Operating Officer of ARTES Medical, Inc., a San Diego based, medical device company with a one-of-a-kind, patented microsphere technology for permanent soft tissue bulking particularly of deep facial wrinkles. From 1998 to 2002, Dr. Ehrlich was Vice President of SerOptix, Inc., Woburn, MA for which he initiated its fluorescence spectroscopy program, which resulted in a technology for the rapid detection of infectious diseases in transfusion blood such as HIV, Hepatitis C, among others. From 1982 to 1997, He was a partner in Waverly Capital which provided consulting services to assist in technical and financial growth in diverse areas, primarily in the oil and gas industries, specifically research and development in drilling, logging and hydrocarbon extraction in shale and stripper oil wells. From 1979 to 1982, Dr. Ehrlich was an Assistant Professor of Physics at City University of New York, Brooklyn College, where he directed research programs in the use of...

Read More